Cited 0 times in Scipus Cited Count

A phase 1/2a, dose-escalation, safety, and preliminary efficacy study of the RKP00156 vaginal tablet in healthy women and patients with cervical intraepithelial neoplasia 2

DC Field Value Language
dc.contributor.authorCho, HW-
dc.contributor.authorJeong, S-
dc.contributor.authorSong, SH-
dc.contributor.authorKim, YT-
dc.contributor.authorKim, JW-
dc.contributor.authorCho, CH-
dc.contributor.authorHur, SY-
dc.contributor.authorChang, SJ-
dc.contributor.authorKim, YM-
dc.contributor.authorLee, JK-
dc.date.accessioned2024-09-27T00:19:50Z-
dc.date.available2024-09-27T00:19:50Z-
dc.date.issued2024-
dc.identifier.issn2005-0380-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32814-
dc.description.abstractObjective: This study aimed to determine the safety and efficacy of the RKP00156 vaginal tablet, a CDK9 inhibitor, in healthy women and patients with cervical intraepithelial neoplasia grade 2 (CIN2). Methods: We conducted a phase 1/2a clinical trial of RKP00156. In step 1, RKP00156 at a dose of 10, 25, or 50 mg or a placebo tablet was administered transvaginally to 24 healthy women. In step 2, RKP00156 at a dose of 10, 25, or 50 mg or a placebo tablet was administered once daily for 4 weeks in 62 patients with CIN2. The primary endpoints of this trial were the safety of RKP00156 and the change in the human papillomavirus (HPV) viral load. Results: A total of 86 patients were enrolled and randomized. RKP00156 administration did not cause serious drug-associated adverse events (AEs). Although no significant difference in the HPV viral load was found between the experimental and placebo groups, a reduction in the HPV viral load was observed in the 25 mg-dose group (−98.61%; 95% confidence interval=−99.83%, 4.52%; p=0.046) after treatment completion in patients with a high HPV viral load, despite a lack of statistical power. No differences in histologic regression and HPV clearance were observed. Conclusion: The safety of RKP00156 was proved with no serious AEs. Although the study did not show any significance in histologic regression and HPV clearance, our findings indicate that RKP00156 may have a possibility of short-term inhibitory effect on HPV replication in patients with higher viral loads.-
dc.language.isoen-
dc.subject.MESHAdministration, Intravaginal-
dc.subject.MESHAdult-
dc.subject.MESHCyclin-Dependent Kinase 9-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPapillomaviridae-
dc.subject.MESHPapillomavirus Infections-
dc.subject.MESHTablets-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHUterine Cervical Dysplasia-
dc.subject.MESHUterine Cervical Neoplasms-
dc.subject.MESHViral Load-
dc.subject.MESHYoung Adult-
dc.titleA phase 1/2a, dose-escalation, safety, and preliminary efficacy study of the RKP00156 vaginal tablet in healthy women and patients with cervical intraepithelial neoplasia 2-
dc.typeArticle-
dc.identifier.pmid38330377-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262905-
dc.subject.keywordHuman Papillomavirus Viruses-
dc.subject.keywordUterine Cervical Dysplasia-
dc.subject.keywordViral Load-
dc.subject.keywordViral Replication Compartments-
dc.contributor.affiliatedAuthorChang, SJ-
dc.type.localJournal Papers-
dc.identifier.doi10.3802/jgo.2024.35.e52-
dc.citation.titleJournal of gynecologic oncology-
dc.citation.volume35-
dc.citation.number4-
dc.citation.date2024-
dc.citation.startPagee52-
dc.citation.endPagee52-
dc.identifier.bibliographicCitationJournal of gynecologic oncology, 35(4). : e52-e52, 2024-
dc.identifier.eissn2005-0399-
dc.relation.journalidJ020050380-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Obstetrics & Gynecology
Files in This Item:
38330377.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse